Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted its pre-approval inspection (PAI) and GMP inspection from 22 August to 26 August 2022, of Unit at Raleigh, North Carolina, USA, (owned by Aurolife Pharma LLC, a wholly owned subsidiary of the company) established for manufacturing MDI (Metered Dose Inhalers) and Derma products. The Unit has filed 2 Derma products and 1 MDI product. At the end of the inspection, Aurolife has been issued a Form 483 with 1 observation and the observation is procedural in nature and there are no data integrity issues. Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
